Literature DB >> 19407320

Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials.

Richard T Silver, Jorge Cortes, Roger Waltzman, Manisha Mone, Hagop Kantarjian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19407320      PMCID： PMC2675690          DOI： 10.3324/haematol.2009.006999

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  5 in total

1.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

Authors:  Charles L Sawyers; Andreas Hochhaus; Eric Feldman; John M Goldman; Carole B Miller; Oliver G Ottmann; Charles A Schiffer; Moshe Talpaz; Francois Guilhot; Michael W N Deininger; Thomas Fischer; Steve G O'Brien; Richard M Stone; Carlo B Gambacorti-Passerini; Nigel H Russell; Jose J Reiffers; Thomas C Shea; Bernard Chapuis; Steven Coutre; Sante Tura; Enrica Morra; Richard A Larson; Alan Saven; Christian Peschel; Alois Gratwohl; Franco Mandelli; Monique Ben-Am; Insa Gathmann; Renaud Capdeville; Ronald L Paquette; Brian J Druker
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

2.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

Authors:  Moshe Talpaz; Richard T Silver; Brian J Druker; John M Goldman; Carlo Gambacorti-Passerini; Francois Guilhot; Charles A Schiffer; Thomas Fischer; Michael W N Deininger; Anne L Lennard; Andreas Hochhaus; Oliver G Ottmann; Alois Gratwohl; Michele Baccarani; Richard Stone; Sante Tura; Francois-Xavier Mahon; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Hagop M Kantarjian; Charles L Sawyers
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

3.  The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.

Authors:  Francesca Palandri; Fausto Castagnetti; Giuliana Alimena; Nicoletta Testoni; Massimo Breccia; Simona Luatti; Giovanna Rege-Cambrin; Fabio Stagno; Giorgina Specchia; Bruno Martino; Luciano Levato; Serena Merante; Anna Maria Liberati; Fabrizio Pane; Giuseppe Saglio; Daniele Alberti; Giovanni Martinelli; Michele Baccarani; Gianantonio Rosti
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

Review 4.  Accelerated and blastic phases of chronic myelogenous leukemia.

Authors:  Francis J Giles; Jorge E Cortes; Hagop M Kantarjian; Susan M O'Brien
Journal:  Hematol Oncol Clin North Am       Date:  2004-06       Impact factor: 3.722

5.  Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.

Authors:  Francesca Palandri; Fausto Castagnetti; Nicoletta Testoni; Simona Luatti; Giulia Marzocchi; Simona Bassi; Massimo Breccia; Giuliana Alimena; Ester Pungolino; Giovanna Rege-Cambrin; Riccardo Varaldo; Maurizio Miglino; Giorgina Specchia; Eliana Zuffa; Felicetto Ferrara; Monica Bocchia; Giuseppe Saglio; Fabrizio Pane; Daniele Alberti; Giovanni Martinelli; Michele Baccarani; Gianantonio Rosti
Journal:  Haematologica       Date:  2008-10-06       Impact factor: 9.941
  5 in total
  12 in total

Review 1.  We do still transplant CML, don't we?

Authors:  Charles F Craddock
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.

Authors:  Nitin Jain; Koen van Besien
Journal:  Hematol Oncol Clin North Am       Date:  2011-10       Impact factor: 3.722

3.  Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy.

Authors:  Zimu Gong; L Jeffrey Medeiros; Jorge E Cortes; Zi Chen; Lan Zheng; Yan Li; Shi Bai; Pei Lin; Roberto N Miranda; Jeffrey L Jorgensen; Timothy J McDonnell; Wei Wang; Hagop M Kantarjian; Shimin Hu
Journal:  Blood Adv       Date:  2017-12-08

4.  A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia.

Authors:  Janice P Dutcher; Evelyn L Morris; Bruce Gaynor; Elisabeth Paietta; Peter H Wiernik
Journal:  Med Oncol       Date:  2009-08-21       Impact factor: 3.064

Review 5.  Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase.

Authors:  Sudipto Mukherjee; Matt Kalaycio
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

Review 6.  Best Practices in Chronic Myeloid Leukemia Monitoring and Management.

Authors:  Simona Soverini; Caterina De Benedittis; Manuela Mancini; Giovanni Martinelli
Journal:  Oncologist       Date:  2016-03-31

7.  Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.

Authors:  Kensuke Usuki; Arinobu Tojo; Yasuhiro Maeda; Yukio Kobayashi; Akira Matsuda; Kazuma Ohyashiki; Chiaki Nakaseko; Tatsuya Kawaguchi; Hideo Tanaka; Koichi Miyamura; Yasushi Miyazaki; Shinichiro Okamoto; Kenji Oritani; Masaya Okada; Noriko Usui; Tadashi Nagai; Taro Amagasaki; Aira Wanajo; Tomoki Naoe
Journal:  Int J Hematol       Date:  2012-02-23       Impact factor: 2.490

8.  In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.

Authors:  Simona Soverini; Caterina De Benedittis; Fausto Castagnetti; Gabriele Gugliotta; Manuela Mancini; Luana Bavaro; Katerina Machova Polakova; Jana Linhartova; Alessandra Iurlo; Domenico Russo; Fabrizio Pane; Giuseppe Saglio; Gianantonio Rosti; Michele Cavo; Michele Baccarani; Giovanni Martinelli
Journal:  BMC Cancer       Date:  2016-08-02       Impact factor: 4.430

9.  A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression.

Authors:  George Giotopoulos; Louise van der Weyden; Hikari Osaki; Alistair G Rust; Paolo Gallipoli; Eshwar Meduri; Sarah J Horton; Wai-In Chan; Donna Foster; Rab K Prinjha; John E Pimanda; Daniel G Tenen; George S Vassiliou; Steffen Koschmieder; David J Adams; Brian J P Huntly
Journal:  J Exp Med       Date:  2015-08-24       Impact factor: 14.307

Review 10.  New Developments in Chronic Myeloid Leukemia: Implications for Therapy.

Authors:  Sanaz Tabarestani; Abolfazl Movafagh
Journal:  Iran J Cancer Prev       Date:  2016-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.